Respiratory Viruses

17

Sep, 2020

Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets

Tags: ,

Authors 

Rachel M Reeves, Maarten van Wijhe, Sabine Tong, Toni Lehtonen, Luca Stona, Anne C Teirlinck, Liliana Vazquez Fernandez, You Li, Carlo Giaquinto, Thea Kølsen Fischer, Clarisse Demont, Terho Heikkinen, Irene Speltra, Michiel van Boven, Håkon Bøås, Harry Campbell, RESCEU Investigators

Background

Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection (RTI) in young children. Registries provide opportunities to explore RSV epidemiology and burden.

Methods

We explored routinely collected hospital data on RSV in children aged < 5 years in 7 European countries. We compare RSV-associated admission rates, age, seasonality, and time trends between countries.

Read
world patient safety day 2020

16

Sep, 2020

World Patient Safety Day | 2020

Tags: , ,

Now is the time to “Speak up for health worker safety!” Working in stressful environments makes health workers more prone to errors which can lead to patient harm. (more…)

11

Sep, 2020

World Sepsis Day

Tags:

The 13th September marks World Sepsis Day. Infectious diseases remains a leading cause of death for children. The burden of this problem is particularly felt in sub-Saharan Africa and in Central and Southern Asia, due to the high prevalence of comorbidities.

Together with GARDP and St George’s University of London and partners across the world, we have collaborated on different projects aiming to develop and deliver innovative real world research that will be used to bring new and improved treatment and prevention options for babies and children that are affordable and available as fast as possible. These include both clinical trials and observational studies to assess safety and dosing of antibiotics in neonates and to collect clinical information on neonatal sepsis in different countries worldwide.

Building on our existing clinical trial networks, together with our partners we are working to:

  • Accelerate the paediatric development of key new antibiotics and obtain a paediatric indication or recommendation for important older antibiotics.
  • Support the update of paediatric guidelines with evidence, taking into account an evolving epidemiology globally.
  • Build on existing paediatric clinical trial networks to develop key activities including regulatory and implementation studies.

Discover more about our activities in the field of severe infections.

#worldsepsisday #wscspotlight

9

Sep, 2020

Actual problems of HIV Infection: Mother and Child

Tags: ,

Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15th September. The Penta session What’s new for children and women living with HIV: interactive clinical day with Penta will look at new data on ART in pregnancy and newborns, resistance and recommendations for 1st, 2nd and further lines, supporting our adolescents and coinfections.

Register to conference!

7

Sep, 2020

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

Tags:

Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network

Published in: Clin infect Dis2020;26.ciaa006

Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents.

Methods Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) underwent 24-hour pharmacokinetic profiling in their third trimester and postpartum. Dolutegravir exposure in the third trimester was considered adequate if geometric mean unbound, pharmacologically active, minimal plasma concentrations (Cmin, unbound) and ≥90% of individual Cmin, unbound levels were >0.85 µg/L, the proposed 90% inhibitory concentration for unbound dolutegravir. Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) for comparison of total and unbound pharmacokinetic parameters in the third trimester and postpartum were calculated, including the metabolic ratio for dolutegravir-glucuronide. Safety and virological data were collected.

Results Seventeen women (76% black) were enrolled (25 evaluable pharmacokinetic profiles; 15 in the third trimester, 10 in postpartum). In the third trimester, geometric mean (coefficient of variation, %) Cmin, unbound was 2.87 (87) µg/L and 93% of individual Cmin, unbound levels were >0.85 µg/L. The GMR (90% CI) in the third trimester vs postpartum was 0.86 (.68-1.10) for area under the curve (AUC0-24h), and for Cmax, 0.93 (.77-1.13). GMR (90% CI) for the trough concentrations was 0.71 (.49-1.02), based on total dolutegravir concentrations. Four serious adverse events were reported, unlikely related to dolutegravir. The HIV polymerase chain reaction test was negative in 14/17 infants (result unknown for 3 infants).

Conclusions Pharmacokinetic changes for dolutegravir in late pregnancy are not clinically relevant and support the use of dolutegravir 50 mg once daily with food in pregnancy.

7

Sep, 2020

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study

 

Authors: Bukkems V, Necsoi C, Hidalgo Tenorio C, et al. PANNA Network

Published in: Clin infect Dis2020; 24;ciaa488.

Abstract This phase-IV study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 HIV-1-positive women. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir Ctrough was reduced by 77%, with 85% of pregnant women having a Ctrough below the EC90.

7

Sep, 2020

NeoVanc trial in the final stretch towards completion!

Tags: ,

The second trial in neonatal sepsis sponsored by Penta is now in its final stretch towards completion. This trial is part of the NeoVanc project, which aimed to analyze the adaptability of an off-label medicine, vancomycin, to the specific needs of neonates and infants, by developing an optimal dosing regimen. Coordinated by Penta and funded by the European Commission’s 7th Framework Programme, NeoVanc has successfully recruited almost 250 participants, and involved more than 20 sites in 5 European countries. This randomised, open label, phase IIb study compares the efficacy, safety and pharmacokinetics of an optimised dosing regimen with a standard dosing regimen of vancomycin in neonates and infants with late onset bacterial sepsis. The study team is currently developing publications to present the results to the wider public.

3

Sep, 2020

WSC Spotlight: Sepsis, Pandemics, and Antimicrobial Resistance – Global Health Threats of the 21st Century

Tags:

On September 9th, the WHO and the Global Sepsis Alliance (GSA) will co-host the free online congress “WSC Spotlight Sepsis. Pandemics, and Antimicrobial Resistance – Global Health Threats of the 21st Century”.

Through 6 distinctive sessions, the WSC Spotlight will give an overview of the global epidemiology and burden of sepsis and AMR, exploring innovative, novel, and cost-effective approaches for the prevention and treatment of both severe infections and antimicrobial resistance.

Speakers will discuss lessons learned and challenges from the COVID-19 pandemic and recent Ebola out­breaks, and how this has impacted the fight against sepsis and AMR.

The congress take place just 4 days before World Sepsis Day on 13 September 2020. It will bring together people (representatives of international and national healthcare authorities, NGOs, policymakers, patients, patient advocacy groups, clinical scientists, researchers) from across the world, who are committed to improve AMR and sepsis healthcare outcomes.

We are proud to announce that our collaborators Mike Sharland from St George’s, University of London and Ilaria Capua from Emerging Pathogens Institute, University of Florida will intervene during session 3.

Ilaria Capua will provide the  KeyNote on the One-Health-Approach to AMR and Global Health Threats, with Mike Sharland providing an overview of AMR in neonates and children with sepsis in low and middle-income countries.

 

Don’t miss out – register here!

2

Sep, 2020

SARS‐CoV‐2 infection in people living with HIV: a systematic review

Tags: , , ,

Background and setting Little is known about SARS‐CoV‐2 impact on some vulnerable subgroups, such as people living with HIV/AIDS (PLWHA). In our study we reviewed the current knowledge on SARS‐CoV‐2 cases in PLWHA.

Methods A systematic review was conducted by searching the MEDLINE, EMBASE and Google Scholar databases. Studies reporting data on PLWHA affected by SARS‐CoV‐2 were considered for inclusion. The aim of this study was the systematic characterization of cases of SARS‐CoV‐2 infection among PLWHA, particularly focusing on age, clinical findings at diagnosis, radiological features, therapeutic management and clinical outcomes.

Results Twenty three relevant articles were identified, which reported 164 adults with both HIV and SARS‐CoV‐2 infection. Of those, the large majority were males (120/142, 84.5%), often with one or more comorbidities. Fifteen cases needed intensive care treatment and 16 died. For each group, respectively three patients had underlying comorbidities. There were no studies on children. The included studies were mostly retrospective or case series/reports (19 studies). The overall risk of bias was moderate, due to the study types and characteristics.

Conclusion It is still unclear if HIV infection may influence SARS‐CoV‐2 infection and disease course, however some PLWHA and particularly males affected by ARV‐related complications may be at greater risk of severe Covid‐19 course.

NEWSLETTER

We would like to update you on our recent activities